Saladax Biomedical company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Loan | Alive

Total Raised


Last Raised

$100K | 2 yrs ago

About Saladax Biomedical

Saladax Biomedical develops and commercializes diagnostic assays for the practical delivery of personalized medicine. The company's line of MyCare assays improves the efficacy of existing drugs through optimized dosing. Saladax's initial focus is oncology, with a portfolio of 13 chemotherapy drug dose management assays in various stages of development. Three MyCare assays are currently offered to the oncology community: My5-FU, MyPaclitaxel and MyDocetaxel. Saladax's MyCare line also serves the central nervous system (CNS) field, with two antipsychotic drug dose management assays.

Saladax Biomedical Headquarter Location

116 Research Drive

Bethlehem, Pennsylvania, 18015,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Saladax Biomedical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Saladax Biomedical is included in 3 Expert Collections, including Medical Devices.


Medical Devices

11,590 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Health IT

7,900 items

Saladax Biomedical Patents

Saladax Biomedical has filed 26 patents.

The 3 most popular patent topics include:

  • Fluoroarenes
  • Immunology
  • Nootropics
patents chart

Application Date

Grant Date


Related Topics




Proteins, Transcription factors, Clusters of differentiation, Molecular biology, Human proteins


Application Date


Grant Date



Related Topics

Proteins, Transcription factors, Clusters of differentiation, Molecular biology, Human proteins



Latest Saladax Biomedical News

Saladax Biomedical, Inc. Acquires Intellectual Property Portfolio for Antipsychotic Drug Tests

Apr 5, 2022

April 05, 2022 09:05 AM Eastern Daylight Time BETHLEHEM, Pa.--( BUSINESS WIRE )--Saladax Biomedical, Inc. (Saladax) is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. This intellectual property (IP) portfolio includes 17 patent families and has resulted in 33 U.S. patents and 296 patents in ex-U.S. countries. This IP, along with the current Saladax IP, covers the major antipsychotic drugs that are prescribed worldwide and places Saladax in a premier position in the antipsychotic drug testing field. With this IP portfolio, Saladax has developed tests for chemistry analyzers commonly found in hospitals and a point-of-care instrument that can be used where centralized testing is not possible. These tests address a significant unmet clinical need for patients with serious mental illness (SMI) by providing rapid, actionable results to health care professionals (HCP). International and U.S. clinical guidelines have recently been established recommending antipsychotic drug testing. The availability of these tools will greatly enhance the ability of health care professionals to better manage their patients in real time. SMI is a significant public health concern. The estimated economic impact of SMI worldwide is more than $2.5 trillion each year with the number of people that SMI affects growing rapidly. In the U.S. current data shows that more than 13 million adults in the U.S. experienced SMI in the past year. That is more than 3% of the adult population.1 Saladax is well positioned as the leading diagnostic company in the field of antipsychotic drug testing with a full panel of antipsychotic tests already on the market and a solid pipeline of new products. “This is a very exciting time for Saladax and the field of therapeutic drug monitoring (TDM).” stated Sal Salamone, Founder and CEO of Saladax. “The availability of antipsychotic testing is arguably the most significant step in the field of TDM since the launch of the Abbott Diagnostics TDx platform back in the 1980’s.” About Saladax Biomedical, Inc. Headquartered in Bethlehem, PA, Saladax Biomedical, Inc. is a privately held company that develops, manufactures, and markets assays that provide rapid therapeutic drug levels for essential and life-saving medicines prescribed by psychiatrists and oncologists. Since 2007, Saladax's proprietary technology has been used in clinical laboratories or point-of-care settings to assist clinicians in monitoring and optimizing patient care. Additionally, the company collaborates with leading pharmaceutical companies to develop tests for clinical trials and companion diagnostics. For more information, visit . Bessonova L, Ogden K, The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature review 2011. doi: 10.2147/CEOR.S259338

Saladax Biomedical Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Saladax Biomedical Rank

  • When was Saladax Biomedical founded?

    Saladax Biomedical was founded in 2004.

  • Where is Saladax Biomedical's headquarters?

    Saladax Biomedical's headquarters is located at 116 Research Drive, Bethlehem.

  • What is Saladax Biomedical's latest funding round?

    Saladax Biomedical's latest funding round is Loan.

  • How much did Saladax Biomedical raise?

    Saladax Biomedical raised a total of $49.86M.

  • Who are the investors of Saladax Biomedical?

    Investors of Saladax Biomedical include Ben Franklin Technology Partners of Northeastern PA, Fosun Pharmaceutical, GE Capital, Life Sciences Greenhouse of Central Pennsylvania, Delaware Crossing Investment Group and 5 more.

  • Who are Saladax Biomedical's competitors?

    Competitors of Saladax Biomedical include WaveForm Diabetes, Integrated Diagnostics, Foundation Medicine, Third Eye Diagnostics, EraGen Biosciences and 11 more.

You May Also Like

MC Laboratory

People today suffer from stress and disturbed eating habits which can increase wastes in blood and cause interrupted blood flow. MC FAN is a blood fluidity measurement device (blood fluidity analyzer) which simulates capillary vessels. When a blood sample is applied to the analyzer, the condition of the blood can be displayed on the TV monitor in real time.

Meditsynskaya elektronika

OOO Meditsynskaya elektronika (Medical electronics) is engaged in production of portable devices (glucometers) for noninvasive (painless) monitoring of blood sugar content in human blood.

Pelikan Technologies

Pelikan Technologies is dedicated to the development of hand-held diagnostic and monitoring devices capable of improving the screening and management of a variety of medical conditions. In addition to diabetes, the company's versatile technology platform has applications across a range of other medical conditions that involve blood screening and monitoring. Point-of-care testing and diagnostic panel test systems also represent markets that can benefit from Pelikan's technology. The Pelikan Sun can improve the quality of life for people with diabetes by combining several of the company's technologies into the most convenient and effective blood glucose self-monitoring device available. Pelikan's line of diabetes management tools will address the pain and inconvenience that has stymied the industry's manufacturers, and plagued people with diabetes, contributing to poor blood glucose monitoring compliance. By targeting these barr

Cellpoint Diagnostics

CellPoint Diagnostics is developing diagnostic, monitoring, and molecular analytical tools for cancer. Its technology captures and analyzes circulating tumor cells ("CTCs") directly from patient blood. Scientific and clinical data have demonstrated that CTCs are derived from the primary tumor, and the assessment of the number of CTCs in the blood has been shown to accurately predict survival for cancer patients.

Tensys Medical

Tensys Medical Tensys has developed a continuous, non-invasive blood pressure monitoring technology for cardiac output assessment that is easy to administer and comfortable for the patient. San Diego, CA.


AiMedics is an Australian company developing a device for non-invasive measurement of nocturnal hypoglycaemia (low blood sugar) for Type 1 juvenile diabetes from UTS, Sydney.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.